BioNTech SE

Youtube Subscribe

Open: 97.21 Close: 97.96 Change: 0.75

Are you still looking for information about BioNTech SE Stock? An AI summarized it for you.

The game is changing. There is a new strategy to evaluate BioNTech SE fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: price, BioNTech, vaccine, Moderna, company, develop, COVID19, …

Concept Map

Semantic Network

Stock Summary

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. FixVac product candidates are in Phase II clinical trials for advanced melanoma, including BNT111, BNT112, BN111.

Today's Summary

European Patent office declares Moderna mRNA patent invalid. Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older. Pfizers announced a non-cash charge for inventory write-offs and other charges related.

Today's News

European Patent Office declares contested mRNA patent owned by Moderna (MRNA) invalid, handing a win to BioNTech in a patent dispute between the two coronavirus vaccine makers. European Patent office declares Moderna mRNA patent invalid. Germany-based biotechnology company focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older. Pfizer and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19. Pfizer announced a non-cash charge for inventory write-offs and other charges related to COMIRNATY of $0.9 billion. The current BioNTech SE [ BNTX ] share price is $97.96 USD today. The current share price for the company is 36, which is 28% below its historic median score of 50. COVID-19 vaccines (COMIRNATY®) by Pfizer and BioNTech are based on BioNTecs proprietary mRNA technology and were developed by both companies. Pfizer/BioNTech Prix Galien Canada Innovative Product Award emergency use authorizations. BioNTech SE price would move from $106.14 to $184.88, which is up 74% to $180.85 in the next five years. In the first half of 2024, the price will climb to $102.88; in the second half, price would add $0.94 and close the year at $103.82. In 2030, BioNTecSE price would rise to $2282534  in 71 comparable Suzwarning Residents carrier WB BioNTech SE price would move from $125 to $211, which is up 69% in five years. In the first half of 2024, the price would climb to $118; in the second half, price would add $7 and close the year at $125. In 2030, BioNTecSE price would rise from $211 to $265. Moderna and BioNTech are pioneering companies in messenger RNA technology, known for their fast development of highly effective COVID-19 vaccines. Moderna (MRNA) and Biontech (BNTX) are two pioneering companies known for developing highly effective vaccines. Moderna and BioNTech are developing combinatory vaccines, targeting covid & influenza. Moderna is developing individualized oncology therapy for lung cancer. Biontech Se s forecast annual revenue growth rate of -21.04% is not forecast to beat the US Biotechnology industrys average forecast revenue growth of 35.08%. Wall Street analysts predict that BionTech Se s share price could reach $142.75 by Nov 14, 2024. The average Bion tech Se stock price prediction forecasts a potential upside of 45.72%.

Stock Profile

"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany."

Keywords

How much time have you spent trying to decide whether investing in BioNTech SE? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: price, BioNTech, vaccine, Moderna, company, develop, COVID19, and the most common words in the summary are: stock, biontech, se, price, market, news, vaccine, . One of the sentences in the summary was: Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #stock #biontech #se #price #market #news #vaccine.

Read more →

Youtube Subscribe

---